Vaccines Boost Priority Profile Of US FDA’s Biologic Center 2019 Approvals
Tropical diseases were not neglected by the Center for Biologics Evaluation and Research in 2019, producing three novel vaccines (which earned three priority review vouchers) and tilting the approval class toward expedited review programs.
You may also be interested in...
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Nigeria's monkeypox outbreak represents opportunity for Danish company still looking to overcome cancer vaccine setback.